1. Study identification
EU PAS Register NumberEUPAS5249
Official titleMetformin use in renal impairment
Study title acronym
Study typeObservational study
Brief description of the study
Was this study requested by a regulator?Yes: EMA
Is the study required by a Risk Management Plan (RMP)?
Not applicable
Regulatory procedure number (RMP Category 1 and 2 studies only)
Other study registration identification numbers and URLs as applicable
2. Research centres and Investigator details
Coordinating study entity
Department/Research groupDepartment of Clinical Epidemiology
Organisation/affiliationAarhus University / Aarhus University Hospital
Details of (Primary) lead investigator
Title Professor
Last name Sørensen
First name Henrik Toft
Is this study being carried out with the collaboration of a research network?
No
Other centres where this study is being conducted
Multiple centres
In total how many centres are involved in this Study?2
Boston Collaborative Drug Surveillance Program, Boston, USA
Countries in which this study is being conducted
International study
Denmark
United Kingdom
3. Study timelines: initial administrative steps, progress reports and final report
PlannedActual
Date when funding contract was signed31/07/201331/07/2013
Start date of data collection16/12/201316/12/2013
Start date of data analysis16/12/201316/12/2013
Date of interim report, if expected31/03/201430/04/2014
Date of final study report30/06/201430/06/2014
4. Sources of funding
Please provide estimates of the percentage of funding by source for this study
Names(s)Approximate % funding
Pharmaceutical companies
Charities
Government body
Research councils
EU funding scheme
OtherEMA100
5. Contact details for enquiries
Scientific Enquiries
Title Dr
Last name Ehrenstein
First name Vera
Address line 1Dept of Clinical Epidemiology
Address line 2Aarhus University Hospital
Address line 3Olof Palmes Alle 43-45
CityAarhus N
Postcode8200
CountryDenmark
Phone number (incl. country code)49-17663169720
Alternative phone number
Fax number (incl. country code)
Public Enquiries
Title Professor
Last name Sørensen
First name Henrik Toft
Address line 1Olof Palmes Allé 43-45
Address line 2
Address line 3
CityAarhus N
Postcode8200
CountryDenmark
Phone number (incl. country code)45-87168063
Alternative phone number
Fax number (incl. country code)45-87167215
6. Study drug(s) information
Single-Constituent (Substance INN)METFORMIN
7. Medical conditions to be studied
Medical condition(s)Yes
Renal impairment
Lactic acidosis
8. Population under study
Age
Adults (18 - 44 years)
Adults (45 - 64 years)
Adults (65 - 74 years)
Adults (75 years and over)
Sex
Male
Female
Other population
Renal impaired
9. Number of subjects
Estimated total number of subjects22000
10. Source of data
Is this study being carried out with an established data source?Yes
Data sources registered with ENCePP
Sources of data
Administrative database, e.g. claims database
Routine primary care electronic patient registry
Pharmacy dispensing records
11. Scope of the study
What is the scope of the study?
Drug utilisation study
Primary scope : Drug utilisation study
12. Main objective(s)
What is the main objective of the study?
1. To conduct a systematic review of literature relevant to metformin use and renal impairment
2. To examine a.prevalence of renal impairment and other characteristics among new and prevalent users of metformin; b) use of metformin in patients with type 2 diabetes according to stage of renal function impairment c) Safety of metformin regarding renal impairment and lactic acidosis
Are there primary outcomes?Yes
lactic acidosis
renal impairment
Are there secondary outcomes?No
13. Study design
What is the design of the study?
Cross-sectional study
Cohort study
Drug utilisation study
14. Follow-up of patients
Will patients be followed up?Yes
Please describe duration of follow up
up to 10 years follow-up from registry data
15. Data analysis plan
Please provide a brief summary of the analysis method
-- Drug utilisation study - cross tabulation of distributions and patient characteristics
-- incidence and prevalence of primary outcomes
-- analysis of risk factors for lactic acidosis